Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Apr 1;3(4):831-838.
doi: 10.3892/ol.2012.567. Epub 2012 Jan 16.

Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: Meta-analysis of randomized controlled trials

Chengyao Zhang  1 , Jiawu Wang, Haitao Gu, Daihua Zhu, Yang Li, Peng Zhu, Yaxu Wang, Jijian Wang
Affiliations

Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: Meta-analysis of randomized controlled trials

Chengyao Zhang et al. Oncol Lett. .

Abstract

The aim of this study was to evaluate the curative effects and safety of capecitabine plus oxaliplatin compared with 5-fluorouracil (5-FU) plus oxaliplatin in patients with metastatic colorectal cancer (MCRC). We searched the Cochrane Central register of Controlled Trials (CENTRAL), PubMed, Ovid, ScienceDirect, EBSCO, EMBASE and conference proceedings for eligible trials. A meta-analysis was performed using Review Manager 5.0. A total of 3,603 cancer patients from 7 trials were analyzed, and the baseline patient characteristics were comparable in all studies. Curative effect outcomes including complete response (CR) (OR=0.78; 95% CI 0.47-1.31; p=0.35), partial response (PR) (OR=0.81; 95% CI 0.65-1.00; p=0.05) and the overall response rate (ORR) (OR=0.85; 95% CI 0.71-1.02; p=0.08) showed similar curative effects between the capecitabine plus oxaliplatin group and the 5-FU plus oxaliplatin group. Moreover, the median overall survival (OS) and progression-free survival (PFS) had no statistically significant differences. Regarding safety, hand-foot syndrome was more frequently observed in the capecitabine plus oxaliplatin group (OR=2.71; 95% CI 2.04-3.61; p<0.00001), while stomatitis and neutropenia were reversed. Other toxic effects had no statistically significant differences between the two groups. Our results showed that capecitabine plus oxaliplatin had similar curative effects to 5-FU plus oxaliplatin, however, it was safer in patients with MCRC.

PubMed Disclaimer

Figures

Table I
Table I
Characteristics of studies included in the meta-analysis.
Table II
Table II
Quality assessment of studies included in the meta-analysis.
Figure 1
Figure 1
Meta-analysis of the complete response rate of capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin for metastatic colorectal cancer.
Figure 2
Figure 2
Meta-analysis of the partial response rate of capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin for metastatic colorectal cancer.
Figure 3
Figure 3
Meta-analysis of the overall response rate of capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin for metastatic colorectal cancer.
Table III
Table III
Analytic results of median OS and PFS.
Figure 4
Figure 4
Meta-analysis of the incidence of hand-foot syndrome using capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin for metastatic colorectal cancer.
Figure 5
Figure 5
Meta-analysis of the incidence of stomatitis in capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin for metastatic colorectal cancer.
Figure 6
Figure 6
Meta-analysis of the incidence of neutropenia in capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin for metastatic colorectal cancer.
Table IV
Table IV
Meta-analysis of partial adverse events.
See this image and copyright information in PMC

References

    1. Jemal A, Siegel R, Ward E. et al. Cancer statistics. CA Cancer J Clin. 2009;57:43–66. - PubMed
    1. Goldberg RM, Rothenberg ML, Van Cutsem E. et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist. 2007;12:38–50. - PubMed
    1. Hoff PM, Ansari R, Batist G. et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;19:2282–2292. - PubMed
    1. Jadad AR, Moore RA, Carroll D, et a1. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. 1996;17:1–12. - PubMed
    1. Rothenberg ML, Cox JV, Butts C. et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol. 2008;19:1720–1726. - PubMed